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Abstract
Background: Posterior reversible encephalopathy is a syndrome highly associated with hypertension and cytotoxic
therapy. The syndrome typically presents with headache, visual abnormality, seizures and characteristic vasogenic
edema on magnetic resonance imaging. The entity warrants a prompt diagnosis to avoid deteriorating consequences.
Case presentation: In this report, we describe a 15-year-old Iranian boy who was diagnosed with mixed connective
tissue disease, and cyclophosphamide pulse therapy was administered. Three days after the second pulse of
cyclophosphamide, when he was receiving prednisolone and hydroxycholoroquine, our patient developed
generalized tonic-clonic seizures. Magnetic resonance imaging findings showed high signal intensities in the
posterior areas of his brain. After 8 days, the brain magnetic resonance imaging abnormalities were resolved
following the control of his blood pressure and antiepileptic treatment. These observations have been indicative
of posterior reversible encephalopathy syndrome. Nevertheless, our patient developed uncontrollable respiratory
distress and eventually died.
Conclusions: To the best of our knowledge, this case is the first report of posterior reversible encephalopathy
syndrome in a patient with mixed connective tissue disease. As the patient developed posterior reversible
encephalopathy syndrome 3 days after cyclophosphamide pulse therapy to reduce the disease activity, it is hard
to accurately determine whether posterior reversible encephalopathy syndrome in this case is a complication of
cyclophosphamide or a condition that resulted from the mixed connective tissue disease flare-up.
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Background
Posterior reversible encephalopathy syndrome (PRES) is
a life-threatening condition which can be characterized
by symmetric involvement of posterior white matter on
magnetic resonance imaging (MRI) and neurological im-
pairments such as seizures, altered mental status, head-
ache, and visual disturbances [1, 2].
PRES has been reported in different conditions such
as hypertensive encephalopathy, eclampsia, throm-
botic thrombocytopenia purpura, and rheumatologic
disorders [3–5].
The mainstay of management of PRES is timely diag-
nosis and discontinuation of causative agents that may
prevent subsequent abnormalities of the central nervous
system.
The extensive use of immunosuppressive therapy and
the autoimmune nature of rheumatologic diseases may
make patients more vulnerable for developing PRES in
the course of disease. Nevertheless, to the best of our
knowledge, PRES has not been reported as a complica-
tion of treatment or a manifestation of disease in pa-
tients with mixed connective tissue disease (MCTD).
In this report, we describe a 15-year-old Iranian boy
with MCTD who presented with PRES 3 days after
cyclophosphamide pulse therapy when he was receiving
a high dose of steroids. Our patient was treated with
antihypertension and antiepileptic medications and a re-
peat MRI scan showed no abnormality 8 days later.* Correspondence: Mozhdehzabihi@gmail.com
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Case presentation
Our patient was a 15-year-old Iranian boy with a 2-year
history of skin ulcer compatible to pyoderma gangreno-
sum. From the onset of his skin problems, he had been re-
ceiving a low dose of steroids, which was increased to 1
mg/kg 2 months prior to admission. He was referred to
our hospital following development of muscle weakness
and severe dyspnea. History-taking revealed a 1-year his-
tory of discoloration of his fingers in cold temperatures. A
physical examination showed scleroderma-like signs of
acrosclerosis and a small mouth orifice with difficulty in
opening. Blood tests showed a remarkable elevation of
muscle enzymes (creatine phosphokinase [CPK] >3000, al-
dolase 39.4 and lactate dehydrogenase [LDH] 1510) and
electromyogram-nerve conduction (EMG-NCV) tests in-
dicated chronic moderate to severe myopathic process.
We performed a muscle biopsy of his left deltoid muscle
that revealed multiple necrotic fibers and extensive inflam-
matory endomysial foci. The laboratory findings showed
antinuclear antibodies (ANA) 1:2500 positive, anti-double-
stranded (ds) DNA 198 positive, anti-SM >200 positive,
anti-SCL-70 >200 positive, anti-centromere >2 positive,
anti-U1 RNP 178.4 positive, white blood cells (WBC)
(from 3500 to 6900 during the hospitalization),
hemoglobin (Hb) 12.3, platelets (PLT) 128,000, and
erythrocyte sedimentation rate (ESR) 56 (normal range
<30). His anticardiolipin, anti-beta 2 glycoprotein I and
lupus anticoagulant antibodies were negative and also his
complement 3 (C3) and complement 4 (C4) levels were in
normal range. Our patient fulfilled the Alarcon-Segovia
diagnostic criteria [6] with positive serology and three of
the five clinical criteria especially Raynaud’s phenomenon,
acrosclerosis, and myositis. Our patient also met the
Kasukawa diagnostic criteria [6] with one common
symptom of Raynaud's, positive serology, and mixed
findings of leukopenia/thrombocytopenia, acrosclerosis,
and muscle weakness. A chest X-ray showed diffuse
pulmonary infiltration and a computed tomography
(CT) scan reported a bronchiolitis obliterans organizing
pneumonia (BOOP) reaction. Further tests also showed
heart failure (ejection fraction [EF] = 30%) and pul-
monary arterial hypertension (pulmonary artery pres-
sure [PAP] = 75 mmHg). Pulmonary embolus was ruled
out by CT angiography. According to the criteria, our
patient was diagnosed with mixed connective tissue
disorder (MCTD), and 1 g intravenous methylpredniso-
lone was administered. Then our patient received 500
mg cyclophosphamide pulse therapy, and was dis-
charged with prednisolone 70 mg daily and hydroxy-
choloroquine 200 mg daily. Our patient received the
second pulse of 500 mg cyclophosphamide 2 weeks
later. Three days after the second cyclophosphamide
pulse when he was receiving prednisolone 70 mg/day,
he developed several generalized tonic-colonic seizures.
After admission to the intensive care unit, he developed
another seizure that lasts 3 minutes. At this time, his
blood pressure was 170/130. Therefore, phenytoin and
antihypertension drugs were prescribed. An MRI scan
of our patient revealed high signal intensities on T2-
weighted images and fluid-attenuated inversion recov-
ery (FLAIR) sequences in the subcortical white matter
of the occipital, posterior parietal, and posterior tem-
poral lobes, and the cerebellum (Fig. 1). After 8 days,
the brain MRI abnormalities had completely been re-
solved. These observations have been indicative of
PRES.
From the first day of his second admission, our patient
presented fever, cough and dyspnea and the laboratory
tests showed creatinine 2.35 mg/dL, urea 182 mg/dL,
WBC 3500, and platelets 75,000. A chest X-ray revealed
extensive pleural effusion. In a peripheral blood smear,
there was no evidence of thrombotic thrombocytopenia
purpura. The serial blood test showed a progressive in-
crease in his creatinine level and decrease in his platelet
count. Therefore, we started rituximab 500 mg for 2
weeks to control the disease flare-up. However, rituxi-
mab was not efficient and we started intravenous im-
munoglobulin (IV Ig) for 5 days. IV Ig did not improve
our patient and we had to initiate plasma exchange.
However, his creatinine level increased and respiratory
symptoms became worse. Dialysis prevented the worsen-
ing of his condition and relieved our patient’s symptoms.
The results from bronchoalveolar lavage (BAL) showed
infection to cytomegalovirus (CMV), Gram-negative ba-
cillus, and candida. Although our patient received
broad-spectrum antibiotics and antifungal agents, his re-
spiratory manifestations were not improved and he was
intubated. After 5 days of intubation, our patient devel-
oped heart arrest and, following 45 minutes of cardio-
pulmonary resuscitation (CRP), our patient died.
Discussion
Posterior reversible encephalopathy syndrome was first
introduced by Hinchey and his colleagues in a study of
15 patients [7].
PRES can be diagnosed in a patient with reversible
neurological manifestations including headache, nausea/
vomiting, visual abnormalities, consciousness impair-
ment, seizure activity, and focal neurologic signs, in con-
junction with bilateral involvement of posterior brain
areas on magnetic resonance imaging [2].
The pathophysiology of PRES remains elusive. How-
ever, it has been suggested that a compromised cerebro-
vascular autoregulation due to acute hypertension may
play a pivotal role. Accordingly, impaired cerebrovascu-
lar regulation may lead to arteriole leakage and cerebral
vasogenic edema [1, 2]. Although the co-occurrence of
hypertension and PRES is remarkable, other possible
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mechanisms have also been reported to be important in
PRES such as disrupted cerebral autoregulatory mecha-
nisms due to autonomic dysfunction [8], breakdown of
blood-brain barrier following cytotoxic agents-induced
endothelial toxicity, autoimmunity, and sepsis [9].
In addition, immunosuppressive agents such as methyl-
prednisolone, dexamethasone, cyclosporine and cyclophos-
phamide have been reported to be related to PRES [10].
Our patient presented PRES 3 days after cyclophos-
phamide pulse therapy when he was receiving a high
dose of prednisolone in the setting of a MCTD flare-up.
On the other hand, clinical signs showed that our pa-
tient developed sepsis concomitant with PRES. There-
fore, we could not accurately determine the main
causative source of PRES among the cyclophosphamide
pulse therapy, prednisolone, sepsis, and the flare-up of
the underlying disease. Our patient had a 2-year history
of taking steroids for his dermatological disorder that
may decrease the importance of maintenance prednisol-
one as the cause of PRES. Most of the reported cases of
PRES are suggested to be due to cytotoxic or steroid
therapy. In the present case, the diagnosis of PRES a few
days following the second pulse of cyclophosphamide
may underscore its offensive effects and may suggest the
cyclophosphamide pulse as a potential cause. Neverthe-
less, several reports show presentation of PRES unattrib-
utable to therapy in patients with rheumatologic
diseases, which suggested it to be a condition resulting
from underlying disease and even, in some cases, PRES
was the first manifestation of the disease [11]. As in our
case, PRES was concomitant with sepsis, therefore sepsis
may play a role in this condition.
From the standpoint of pathogenesis, MCTD may be
strongly suggestive as a cause of PRES. Various studies
highlight that endothelial cell damage resulted from dif-
ferent autoantibodies in MCTD [12]. Along these lines,
vasculopathy has been suggested to be a specific feature
of MCTD that may lead to pulmonary arterial hyperten-
sion, which is responsible for most of the deaths in the
late stages of MCTD [13]. In addition, the dysfunction
of the autonomic system has been shown in MCTD
[14]. Therefore, PRES may be a manifestation of MCTD
Fig. 1 Brain magnetic resonance imaging T2-weighted/fluid-attenuated inversion recovery scan showing high signal intensities in a the subcortical
white matter of occipital, posterior parietal, and posterior temporal lobes and b the cerebellum. c, d Follow-up brain magnetic resonance imaging
T2-weighted/fluid-attenuated inversion recovery scan 8 days after the first imaging showed complete resolution
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in our case because our patient presented PRES during
the disease flare-up.
To the best of our knowledge, a case of PRES in a pa-
tient with mixed connective tissue disease has not yet
been reported. The neurological manifestations of
MCTD have been believed to be less frequent than find-
ings of other systems. Although the main neurological
manifestations of MCTD are trigeminal neuropathy,
headaches, and aseptic meningitis, this report suggests
PRES as a neurological condition which may occur dur-
ing the course of MCTD [15]. Although there is no dif-
ference between our patient and previously reported
cases in terms of PRES characteristics, further reports
are needed for better understanding of PRES in MCTD.
Conclusions
To the best of our knowledge, this case is the first report
of posterior reversible encephalopathy syndrome in a pa-
tient with mixed connective tissue disease. As the patient
developed PRES shortly after the cyclophosphamide pulse,
during an MCTD flare-up, and concomitant with sepsis, it
is hard to determine the accurate cause of PRES in this
case. Taken together, MCTD may be strongly suggestive
as the cause of PRES for the extensive endothelial dysfunc-
tion involved in its pathogenesis.
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